Switch non- chemo maintenance in advanced BTC- a fresh concept. Feasible in LMICS ascopubs.org/doi/10.1200/JC… Purvish Parikh Milind Javle Dr Amol Akhade Dr (Prof). Vijay Patil @virajlav

Purvish Parikh Milind Javle Dr Amol Akhade Dr (Prof). Vijay Patil bhawna sirohi Dr. Shubham Pant Ind J Med Ped Oncology South Asian Journal Of Cancer Vanita Noronha, MBBS MD DM @amolpat

Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy jamanetwork.com/journals/jaman… Dr (Prof). Vijay Patil Dr Amol Akhade MASCC Vanita Noronha, MBBS MD DM Purvish Parikh Ind J Med Ped Oncology South Asian Journal Of Cancer bhawna sirohi

I could not be more proud of ⁦Aaron J. Scott MD⁩ and team for this incredibly important publication about a very complicated space! ⁦ASCO⁩ guidelines for locally advanced #rectalcancer out now! ⁦Journal of Clinical Oncology⁩ ⁦University of Arizona Cancer Center⁩ ⁦University of Arizona COM - Division of Heme/Onc⁩ ascopubs.org/doi/10.1200/JC…

Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy jamanetwork.com/journals/jaman…

Olanzapine as antiemetic prophylaxis in chemotherapy🤢🤮 In this randomized phase 3 study the addition of olanzapine to dexamethasone, palonosetron, and aprepitant improved emesis control in pts receiving moderately emetogenic CT OncoAlert jamanetwork.com/journals/jaman…

We’re pleased to share this new study from Prof Vikas Ostwal and colleagues that was supported by an IASCC clinical trial grant: Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial jamanetwork.com/journals/jaman… #SuppOnc

Our use of ICIs (standard and alternative dosing) in advanced gastric/gastroesophageal adenocarcinomas. ecancer.org/en/journal/art… ecancer Tata Memorial Hospital Prof Vikas Ostwal Anant Ramaswamy Prabhat Bhargava, DM (Medical Oncology) Manan Vora, MD Himanshu Gujarathi

ecancer.org/en/journal/art… Viraj Lavingia Dr Amol Akhade

Low dose IO in MSI H mCRC works- Some data to chew on JCO Global Oncology ascopubs.org/doi/10.1200/GO… Viraj Lavingia Dr Amol Akhade Sujith Sewanti Limaye 🇮🇳🇺🇸 Dr (Prof). Vijay Patil Vanita Noronha, MBBS MD DM ecancer Purvish Parikh Ind J Med Ped Oncology South Asian Journal Of Cancer @sirohi

@imsmart420 ACTREC-TMC Tata Memorial Hospital Anant Ramaswamy Prof Vikas Ostwal Excellent study. Low dose IO works . There is always difference between optimal dose and approved dose. Time to go for Low dose ADC studies , especially for Tdx1 now Daniel Goldstein MD

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study) | JCO Global Oncology ascopubs.org/doi/full/10.12… Anant Ramaswamy Viraj Lavingia Aditya Dhanawat

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study) | JCO Global Oncology ascopubs.org/doi/full/10.12… Arndt Vogel

In yet another study from our group, low dose #immunotherapy alone is almost equally effective to standard dose (CLouD—High Study) | JCO Global Oncology ascopubs.org/doi/full/10.12…

Performance of Low-Dose #Immunotherapy and Standard-Dose Immunotherapy in Microsatellite-Instability-High Metastatic Colorectal Cancer: Real World Data (CLouD High Study) brnw.ch/21wLZ56 Anant Ramaswamy

Prof Vikas Ostwal Anant Ramaswamy Viraj Lavingia Aditya Dhanawat Useful research Prof Vikas Ostwal . 👍👌

ecancer.org/en/journal/art…

Yet more data on this important treatment modality. A serendipity that will save thousands of lives #lowdoseimmunotherapy

EBM 2025 - Registration started - Online link - tmc.gov.in/m_events/Event…

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India | JCO Global Oncology ascopubs.org/doi/10.1200/GO…